Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Omnicell (OMCL) Long-Term Debt Issuances (2016 - 2017)

Omnicell (OMCL) reported Long-Term Debt Issuances of $22.0 million for Q4 2017, down 45.0% year-over-year from $40.0 million in Q4 2016, and down 18.52% on a QoQ basis from $27.0 million in Q3 2017.

Omnicell (OMCL) has 2 years of Long-Term Debt Issuances data on file, last reported at $22.0 million in Q4 2017.

  • Quarterly Long-Term Debt Issuances fell 45.0% year-over-year to $22.0 million in Q4 2017, while the trailing twelve-month figure through Dec 2019 was $22.0 million (down 55.1% YoY) and the FY2024 annual result came in at $166.3 million, changed N/A from the prior year.
  • Long-Term Debt Issuances fell to $22.0 million in Q4 2017 per OMCL's latest filing, from $27.0 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $247.1 million in Q1 2016 and bottomed at -$8000.0 in Q2 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Veeva Systems 30.85 Bn 24.28 Bn 622.47 Mn -
2 BrightSpring Health Services 12.29 Bn 11.41 Bn 482.22 Mn -
3 Healthequity 7.80 Bn 7.48 Bn 256.31 Mn -
4 Hinge Health 4.82 Bn 4.51 Bn 154.23 Mn -
5 Doximity 4.21 Bn 3.46 Bn 125.97 Mn -
6 Waystar Holding 4.18 Bn 4.03 Bn 268.04 Mn 19.80 Mn
7 10x Genomics 3.78 Bn 3.24 Bn 106.18 Mn -
8 Privia Health 2.65 Bn 2.28 Bn 595.71 Mn -
9 Omnicell 1.95 Bn 1.78 Bn 140.36 Mn -
10 Teladoc Health 1.42 Bn 672.39 Mn 562.57 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2017 22.00 Mn
Dec 31, 2017 22.00 Mn
Sep 30, 2017 27.00 Mn
Sep 30, 2017 27.00 Mn
Jun 30, 2017 10.00 Mn
Jun 30, 2017 10.00 Mn
Dec 31, 2016 40.00 Mn
Dec 31, 2016 40.00 Mn
Jun 30, 2016 -8,000.00
Jun 30, 2016 -8,000.00
Mar 31, 2016 247.06 Mn
Mar 31, 2016 247.06 Mn